Open Access

Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease

  • Authors:
    • Maiko Tabuchi
    • Hitomi Minami
    • Yuko Akazawa
    • Miwa Ashida
    • Toshihide Hara
    • Kunihiro Ichinose
    • Moto Kitayama
    • Keiichi Hashiguchi
    • Kayoko Matsushima
    • Naoyuki Yamaguchi
    • Fuminao Takeshima
    • Hisayoshi Kondo
    • Atsushi Kawakami
    • Kazuhiko Nakao
  • View Affiliations

  • Published online on: December 17, 2020     https://doi.org/10.3892/br.2020.1401
  • Article Number: 25
  • Copyright: © Tabuchi et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Gastroesophageal reflux disease (GERD) in systemic sclerosis (SSc) can significantly reduce a patient's quality of life. GERD in SSc is occasionally resistant to conventional anti‑acid treatment. Vonoprazan is an H+/K+‑ATPase blocker that is approved in Japan for treatment of GERD. The aim of the present study was to evaluate the efficacy of vonoprazan in SSc‑related GERD. The frequency scale for symptoms of GERD (FSSG) scores were collected before and after vonoprazan treatment in 15 SSc patients with GERD. Additionally, endoscopic esophagogastroduodenoscopy was performed in select patients. Conventional proton pump inhibitors or histamine‑2 receptor antagonists had been previously administered in 93% (14/15) of the patients. Although the baseline esophagogastroduodenoscopy examination did not show severe erosion in the majority of patients, the mean total FSSG score before vonoprazan treatment was notably high (25.2±10.7) compared to a normal score of <8. After vonoprazan treatment, the FSSG score decreased to 9.6±7.0. The mean improvement rate of the total FSSG, acid reflux and dysmotility scores were 60.8±21.2% (P=0.0004), 67.3±24.8% (P<0.0001) and 55.4±26.0% (P=0.0022), respectively. These results suggest that vonoprazan may be a potentially effective treatment for GERD in patients with SSc.
View Figures
View References

Related Articles

Journal Cover

February-2021
Volume 14 Issue 2

Print ISSN: 2049-9434
Online ISSN:2049-9442

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tabuchi M, Minami H, Akazawa Y, Ashida M, Hara T, Ichinose K, Kitayama M, Hashiguchi K, Matsushima K, Yamaguchi N, Yamaguchi N, et al: Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease. Biomed Rep 14: 25, 2021
APA
Tabuchi, M., Minami, H., Akazawa, Y., Ashida, M., Hara, T., Ichinose, K. ... Nakao, K. (2021). Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease. Biomedical Reports, 14, 25. https://doi.org/10.3892/br.2020.1401
MLA
Tabuchi, M., Minami, H., Akazawa, Y., Ashida, M., Hara, T., Ichinose, K., Kitayama, M., Hashiguchi, K., Matsushima, K., Yamaguchi, N., Takeshima, F., Kondo, H., Kawakami, A., Nakao, K."Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease". Biomedical Reports 14.2 (2021): 25.
Chicago
Tabuchi, M., Minami, H., Akazawa, Y., Ashida, M., Hara, T., Ichinose, K., Kitayama, M., Hashiguchi, K., Matsushima, K., Yamaguchi, N., Takeshima, F., Kondo, H., Kawakami, A., Nakao, K."Use of vonoprazan for management of systemic sclerosis‑related gastroesophageal reflux disease". Biomedical Reports 14, no. 2 (2021): 25. https://doi.org/10.3892/br.2020.1401